Europe faces pivotal moment in global tobacco and nicotine policy debate

As governments prepare for the WHO Framework Convention on Tobacco Control (FCTC) COP11 and the related Meeting of the Parties (MOP4) in Geneva from 15–22 November, Europe finds itself divided over how far to go in regulating tobacco and new nicotine products — balancing public health, fiscal interests, and the influence of a powerful industry.

A crossroads for global tobacco control

Nearly two decades after the WHO Framework Convention on Tobacco Control (FCTC) entered into force, delegates from more than 180 countries will gather in Geneva to assess global progress and consider new measures to curb tobacco use.

The meetings, taking place from 15–22 November 2025, come at a decisive moment. The agenda includes proposals for stricter advertising bans, plain packaging, higher excise taxes, and tighter oversight of emerging nicotine products such as e-cigarettes and heated tobacco.

At the same time, EU member states are debating how far Europe’s stance on tobacco restrictions should go, as Brussels finalises its position for COP11 and prepares forthcoming revisions to the Tobacco Products Directive (TPD) and the Tobacco Excise Directive (TED). The outcomes from Geneva are likely to influence those legislative processes for years to come.

The numbers behind the debate

Tobacco remains the leading cause of preventable death in the European Union, responsible for an estimated 700,000 deaths annually, according to WHO data. Smoking prevalence stands at roughly 23–25 percent, though figures vary widely — from under 10 percent in Sweden, which has embraced alternative nicotine products, to more than 35 percent in parts of Eastern Europe and the Balkans.

Global tobacco use has declined by about one-third since 2000, but progress is uneven. The rapid rise of new nicotine delivery systems — including vapes, nicotine pouches and heated-tobacco devices — has sparked debate over whether these products help smokers quit or simply create new forms of addiction, particularly among young people.

Diverging philosophies: Harm reduction versus prohibition

Public-health experts remain divided on how best to treat nicotine technologies. Some European scientists and regulators, notably in the United Kingdom and Sweden, advocate a harm-reduction model, encouraging the transition from combustible cigarettes to less harmful alternatives. Others, including within the WHO and several EU member states, warn that industry-promoted products risk renormalising nicotine use and undermining decades of progress against smoking.

At COP11 this philosophical divide will likely resurface in debates over Article 5.3 of the FCTC — protecting policy from industry interference — and whether novel products should face the same restrictions as cigarettes. The WHO urges strict controls, citing youth uptake; industry groups counter that over-regulation could push smokers back to cigarettes and stifle innovation.

The European Commission under scrutiny

Within the EU, the European Commission’s handling of tobacco and nicotine policy draws both praise and criticism.

Supporters of tighter controls see the Commission’s comprehensive taxation and advertising bans as vital to public health. But civil-society groups such as the European Network for Smoking and Tobacco Prevention (ENSP) fear that discontinuation of certain NGO operational grants has weakened independent advocacy, leaving room for industry influence.

Meanwhile, several member states — including Italy, Romania, and Bulgaria — have been accused by campaigners of resisting stronger measures due to domestic tobacco interests.

In Poland, tobacco growers organizations have organised a nationwide farmers' demonstration in the capital of the country on Monday 3 November 2025. According to various local media reports, growers are warning that changes and regulations planned by the World Health Organisation (WHO) and the European Commission (EC) would lead to the collapse of tobacco cultivation in Poland. 

In a joint statement, the organizations voiced deep concern over these developments and urged the government to take immediate action before it is too late. Nevertheless, the organisers emphasised that their actions are not “anti-government”.

Under the European Commission’s proposed amendments to the Tobacco Excise Directive (TED), domestic processing plants would be required to provide enormous excise security deposits—up to PLN 300 million (approximately EUR 80 million) per year per entity. Growers say this measure would cause instant bankruptcy for the entire sector.

These tensions in the different countries are shaping the EU’s collective stance for Geneva.

From ambitious draft to “softened” compromise

A leaked EU draft position dated 7 October 2025 outlined far-reaching proposals: possible bans on cigarette filters, flavour prohibitions across all tobacco products, stricter manufacturer disclosure, and the inclusion of all nicotine devices within the FCTC framework.

However, according to later reports from Table.Media and other Brussels sources, a “softened proposal” was circulated to Member States, replacing several binding commitments with more cautious, discretionary language.

• References to an outright filter ban were reportedly replaced by wording on “phasing down filter pollution.”
• Mandatory flavour bans became “consideration of regulation where appropriate.”
• Language treating all nicotine products identically to tobacco was revised to a “case-by-case, evidence-based approach.”

The shift reflects the economic and political sensitivities among EU countries, with manufacturing states opposing outright bans and harm-reduction advocates seeking differentiation for lower-risk products.

This evolution underscores how internal EU negotiations can temper public-health ambition with pragmatism — a dynamic likely to be on display in Geneva.

Big Tobacco’s evolving strategy

Traditional tobacco companies have repositioned themselves as “smoke-free” or “reduced-risk” businesses, investing heavily in alternative nicotine technologies. They argue these products align with public-health objectives by offering consumers less harmful choices.

Critics contend that such claims mask continued dependence on cigarette profits and warn of strategic efforts to delay or dilute regulation through lobbying, PR campaigns, and funding of selective research.

The WHO’s technical reports to COP11 highlight these risks, urging vigilance in applying Article 5.3 to “avoid conflicts of interest between health policy and commercial interests.”

Fiscal and economic dimensions

Beyond health, tobacco remains a vital revenue source: EU excise duties yield over €70 billion annually. Policymakers must balance deterrent pricing against illicit trade and cross-border smuggling, particularly where tax rates diverge.

The ongoing revision of the Tobacco Excise Directive (TED) aims to modernise rules for new nicotine products. Proponents of harmonisation say consistent minimum rates would close loopholes; opponents warn excessive uniformity could burden smaller economies or fuel the black market.

Civil society and transparency

The ENSP’s decision to host its 2025 conference in Belgrade, outside the EU, symbolises shifting dynamics between Brussels and public-health NGOs. Advocates say reduced EU funding constrains their ability to counter industry lobbying at a crucial time.

Transparency groups meanwhile call for stricter adherence to Article 5.3 obligations, ensuring meetings between EU officials and industry representatives are disclosed. The Commission maintains its policymaking remains transparent and independent.

What to watch in Geneva

Delegates at COP11 and MOP4 are expected to debate:

• Global tax harmonisation and extension to novel products;
• Implementation of the Illicit-Trade Protocol and independence of track-and-trace systems;
• Regulation of e-cigarettes, nicotine pouches, and heated-tobacco devices;
• Environmental measures, including potential restrictions on cigarette filters;
• Protection of policymaking from commercial influence under Article 5.3;
• Support for developing nations transitioning away from tobacco cultivation.

The EU’s internal compromises will determine how strongly it advocates these measures on the global stage.

A decisive but nuanced moment

For policymakers, scientists, and civil society, the Geneva meetings mark a pivotal moment in defining the next phase of tobacco and nicotine policy. Europe’s challenge lies in reconciling health protection with innovation and ensuring that future legislation — whether prohibitionist or harm-reduction-based — remains evidence-driven and transparent.

What happens between 15 and 22 November will influence not only global health policy but also the EU’s own credibility as a leader in the fight against tobacco-related disease.

Share this article: